Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society.
Despite the fact that an estimated 60 million people worldwide suffer from neurodegenerative diseases, a population expected to double every 20 years, there are currently no approved disease-modifying therapies or cures available. These diseases devastate patients and their loved ones.
Yumanity is a clinical-stage biopharmaceutical company dedicated to protecting the vitality of the mind. Using innovative technology licensed from Susan Lindquist’s laboratory at MIT’s Whitehead Institute, we are working to identify and develop new, disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).